centrosomal protein 44Genealiases: KIAA1712 · PS1TP3
Q-omics provides the consensus-scored CEP44 profile across patient tissues and cancer cell-line models. CEP44 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, CEP44 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, CEP44 RNA expression shows 20,359 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, THCA, and UVM as cancer lineages where CEP44 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEP44 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEP44 survival associations across molecular data types. CEP44 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEP44 RNA expression–survival associations across cancer types. High CEP44 expression shows unfavorable associations in UVM, THCA, LIHC, HNSC and LGG, but favorable associations in UCS. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for CEP44 RNA expression.
This table summarizes CEP44 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CEP44. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEP44 shows lower tumor expression in THCA, UCEC and LUAD and higher tumor expression in LIHC, CHOL and HNSC. The THCA box plot shows higher CEP44 RNA expression in normal versus tumor tissue (log2 FC = −0.446, t-test p < 0.001).
This table shows molecular features associated with CEP44 in patient tissues and cancer cell lines. In patient samples, CEP44 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CEP44 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
